Apr 21, 2017

Biotech investments are declining under Trump

Biotech investments and acquisitions have been declining this year, Bloomberg found, as investors are weary of Trump's ability to foster a biotech boom.

The stats: Compared to three years ago, exchange-traded funds have lost nearly half of its trading volume, per Bloomberg. Moreover, Bloomberg noted that these acquisitions — pharmaceutical and biotech — are down 13 percent this year, totaling $44 billion last quarter.

The Trump effect: Biotech investors and companies are standing by to see what relevant issues Trump's administration will move forward on, such as tax reform and the eventual Obamacare replacement, before they feel confident in investing more in the industry.

When there is a little bit more clarity on some of the policy issues we could probably see an uptick in M&A.—Jeff Greene, partner at Ernst & Young

The big questions: Will there be more dealmaking when the Obamacare repeal effort is resolved one way or another, or when Scott Gottlieb is confirmed as the next FDA commissioner? Or will it get worse if Trump keeps talking about drug prices?

Go deeper

Syria's darkest chapter

Family room without a family, in Idlib. Photo: Muhammed Said/Anadolu Agency via Getty Images

The worst humanitarian crisis of Syria’s brutal civil war is colliding today with what could be the war’s most dangerous geopolitical showdown, after at least 29 Turkish troops were killed in an airstrike.

The big picture: The fighting is taking place in Idlib in northwest Syria, where a ferocious Syrian and Russian offensive has displaced 1 million civilians and infuriated Turkey, which borders the region.

Go deeperArrow32 mins ago - World

Fear of coronavirus pandemic escalates

Photo: Abdulgani Basheer/AFP/Getty Images

In the blink of an eye, we've entered a new phase on the coronavirus.

The big picture: Italy, Iran and South Korea are at "decisive" points in their responses, the World Health Organization said on Thursday.

Go deeperArrow3 hours ago - Health